SETH LERNER to Mitomycin
This is a "connection" page, showing publications SETH LERNER has written about Mitomycin.
Connection Strength
2.489
-
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr; 207(4):779-788.
Score: 0.771
-
Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma. Cancer Chemother Pharmacol. 2021 06; 87(6):799-805.
Score: 0.730
-
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
Score: 0.688
-
Drug instillation in the management of urinary tract urothelial carcinoma. Curr Opin Urol. 2022 09 01; 32(5):531-535.
Score: 0.201
-
Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003 May-Jun; 21(3):197-205.
Score: 0.053
-
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18; 93(8):597-604.
Score: 0.046